Category: Stock Movers

Analysis, Stock Movers

After Market Losers: Horizon Technology Finance (NASDAQ:HRZN), Caesars Entertainment (NASDAQ:CZR), Walter Energy (NYSE:WLT), Vipshop Holdings Ltd. (NYSE:VIPS)

Horizon Technology Finance (NASDAQ:HRZN) is lower in late trading after the company reported mixed financial results for Q4. Shares are down 0.57% at $14.02, with a 52-week range of $12.77 – $15.51. The closed-end, non-diversified management investment company reported Q4 net investment income of $0.35 per share, compared with the prior-year period’s $0.36 per share. Horizon Technology Finance (HRZN) revenue was $8.78 million, up from … Continue reading After Market Losers: Horizon Technology Finance (NASDAQ:HRZN), Caesars Entertainment (NASDAQ:CZR), Walter Energy (NYSE:WLT), Vipshop Holdings Ltd. (NYSE:VIPS)

Chris Lewis
Analysis, Stock Movers

Intraday Financial Gainers: Comcast (NASDAQ:CMCSA), J.C. Penney (NYSE:JCP), IsoRay, Inc. (NYSEMKT:ISR), Boyd Gaming (NYSE:BYD)

Comcast (NASDAQ:CMCSA) shares firm Tuesday as the company is contemplating a deal with Japanese electronics maker Sharp. Sharp would build liquid crystal display (LCD) televisions with a built-in cable channel receiver, Kyodo reported. The Japanese news agency said Sharp is trying to pursuing growth by focusing on its sluggish LCD TV operations. Comcast did not comment on the potential alliance. In late morning trade, Comcast … Continue reading Intraday Financial Gainers: Comcast (NASDAQ:CMCSA), J.C. Penney (NYSE:JCP), IsoRay, Inc. (NYSEMKT:ISR), Boyd Gaming (NYSE:BYD)

Colin Pettis
BioTech, Stock Movers

BioTech in Focus: Myriad Genetics (NASDAQ:MYGN), Cantel Medical (NYSE:CMN), WuXi (NYSE:WX)

Myriad Genetics (NASDAQ:MYGN) is lower after the molecular diagnostic company disclosed in a regulatory filing Tuesday that the U.S. District Court for the District of Utah has denied the company’s motion for preliminary injunctive relief against Ambry Genetics’s sale of certain testing services that MYGN believes infringes on its patents. Shares are down 9.80% at $34.04, with a 52-week range of $20.02 – $39.15. Myriad … Continue reading BioTech in Focus: Myriad Genetics (NASDAQ:MYGN), Cantel Medical (NYSE:CMN), WuXi (NYSE:WX)

Richard Atkins
Stock Movers

Health Net (NYSE:HNT) Reaffirms Guidance; Perfect World (NASDAQ:PWRD), Wright Medical Group Inc. (NASDAQ:WMGI), Douglas Dynamics (NYSE:PLOW)

Health Net (NYSE:HNT), a managed care company, disclosed in a regulatory filing Monday that it will be reaffirming its earnings guidance for fiscal 2014 at the Barclays Global Healthcare Conference on Tuesday. The company had previously said that it is expecting fiscal 2014 earnings of at least $3.00 per share and revenue of $14.4 billion. Analysts polled by Capital IQ are expecting EPS of $2.39 … Continue reading Health Net (NYSE:HNT) Reaffirms Guidance; Perfect World (NASDAQ:PWRD), Wright Medical Group Inc. (NASDAQ:WMGI), Douglas Dynamics (NYSE:PLOW)

Mark DeFrance
Stock Movers

Financial Movers: National Bank of Greece (NYSE:NBG), Freddie Mac (OTCBB:FMCC), Camtek (NASDAQ:CAMT), Rosetta Genomic (NASDAQ:ROSG)

Shares of National Bank of Greece (NYSE:NBG) are up nearly 10% Monday following Deutsche Bank’s new coverage of the stock at a Buy rating and EUR4.50 price target (approx $6.25 based on Monday’s exchange rate). The rating results from Deutsche Bank’s forecast for a strong recovery in fundamentals for the Greek banking sector. In addition, the bank will release Q4 earnings on March 27. It … Continue reading Financial Movers: National Bank of Greece (NYSE:NBG), Freddie Mac (OTCBB:FMCC), Camtek (NASDAQ:CAMT), Rosetta Genomic (NASDAQ:ROSG)

Richard Atkins
Stock Movers

BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)

In a note issued Friday, Piper Jaffray said the weakness in Regeneron (NASDAQ:REGN) is a buying opportunity, as the firm sees risks to the company’s alirocumab Phase III program as overblown, with neither Regeneron  (NASDAQ:REGN) or its development partner Sanofi (SNY) having seen any neurocognitive adverse events with the drug. The firm reiterates a Buy rating and $376 price target on shares. Deutsche Bank reports Regeneron … Continue reading BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)

Mark Doerr